This article summarizes the guidelines and consensus on cardiovascular diseases at home and abroad issued in February 2022 for everyone to view and download.
2022 SCAI Expert Consensus: Shock Staging
On January 31, 2022, the American Society for Cardiovascular Imaging and Interventional Studies (SCAI) released an updated version of the expert consensus on SCAI shock staging, which improves the classification system for cardiogenic shock (CS). The new version of CS staging continues the "pyramid" setting of the previous edition, continuing to emphasize physical examination, biochemical and hemodynamic indicators, divided into five stages: at risk, beginning, classic, deteriorating and extremis, including the severity of each stage and the path of patient progression or recovery. The revised pyramid has a color scale to indicate the risks of each stage.
Link: guide.medlive.cn/guideline/25098
Article: SCAI Update Cardiogenic Shock Staging, "Pyramid" Advanced Edition Released!
2022 USPSTF Recommendation Statement: Screening for Atrial Fibrillation
The U.S. Preventive Medicine Task Force (USPSTF) statement notes that current evidence is insufficient to assess the benefits and harms of atrial fibrillation screening in people aged ≥50 years, who have not diagnosed atrial fibrillation or have no history of transient ischemic attack (TIA) or stroke.
Link: guide.medlive.cn/guideline/25016
Article: No symptoms, should I screen for atrial fibrillation? The USPSTF recommends so
2022 AHA Scientific Statement: Imaging and monitoring of chronic aortic dissection
All patients who have had acute aortic dissection require lifelong monitoring of the aorta. Imaging plays a central role in medical decision-making in patients with chronic aortic dissection. The 2022 AHA Scientific Statement introduces imaging techniques for chronic aortic dissection, and some new insights may help improve risk stratification and lead to individualized treatment options.
Link: guide.medlive.cn/guideline/25152
Graded diagnosis and treatment technical scheme for county coronary atherosclerotic heart disease
Coronary atherosclerotic heart disease (hereinafter referred to as coronary heart disease) refers to heart disease caused by narrowing, cramping or blocking the lumen of the coronary atherosclerosis, resulting in myocardial ischemia, hypoxia or necrosis. Coronary heart disease has long become the main killer of people's health in developed countries, and with the acceleration of the process of globalization, cardiovascular and cerebrovascular diseases have begun to spread in developing countries. Fully understanding coronary heart disease and the huge disease burden brought about by the disease is of great significance for further study of prevention and treatment strategies. The formulation of this plan will help improve the level of diagnosis and treatment of coronary heart disease in the county and provide integrated and high-quality medical services for patients.
Link: guide.medlive.cn/guideline/25198
County-level classification diagnosis and treatment of dyslipidemia
Dyslipidemia usually includes hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and low-density lipoprotein cholesterol (HDL-C)emia. Among them, elevated levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) are the main risk factors for atherosclerotic cardiovascular disease (ASCVD), and the prevalence has increased year by year in recent years. Lipid-lowering drugs based on statins reduce LDL-C levels, which can significantly reduce the risk of asCVD morbidity and death. However, due to concerns about adverse reactions and other reasons, treatment compliance is not good. The implementation of graded diagnosis and treatment will help to change the current status quo of low control rates of lipid management.
Link: guide.medlive.cn/guideline/25196
Article: The National Health Commission issued the "County-level Classification Diagnosis and Treatment Technical Plan for Dyslipidemia"
County-level hypertension grading diagnosis and treatment technology program
Hypertension is one of the most common chronic diseases, but also the most important risk factor for cardiovascular and cerebrovascular diseases, and its major comorbidities such as stroke, myocardial infarction, heart failure and chronic kidney disease have a high disability rate and fatality rate. Practice has proved that hypertension is a disease that can be prevented and controlled. Reducing blood pressure levels in patients with hypertension and comprehensive management of cardiovascular and cerebrovascular risk factors can significantly reduce stroke and cardiovascular events. The formulation of this plan will help medical institutions in various counties to better implement their functional positioning and better provide integrated and high-quality medical services for hypertensive patients, thereby significantly improving the quality of life of patients and effectively reducing the burden of diseases on the state and patients.
Link: guide.medlive.cn/guideline/25194
2022 EACVI Consensus Part 2: Clinical Applications of Cardiac CT
Cardiac CT is a non-invasive diagnostic tool that can be used to detect and quantify coronary artery stenosis, and this article, as part 2 of the consensus on the clinical application of cardiac CT, focuses on emerging CT techniques and biomarkers, revising the role of cardiac CT in assessing atherosclerotic plaques, cardiomyopathy, structural heart disease, and congenital heart disease.
Evidence for the clinical use of cardiac CT has emerged in recent years, and it has become a comprehensive imaging modality that can provide anatomical and functional information to guide patient management. The 2022 EACVI Consensus introduces emerging CT techniques and biomarkers such as CT-FFR, perfusion imaging, and peri-coronary adipose tissue attenuation. In addition, the role of cardiac CT in the evaluation of atherosclerotic plaque, cardiomyopathy, structural heart disease and congenital heart disease was revised.
Link: guide.medlive.cn/guideline/25154
2022 EAPC Submission: Mental Health Risk Factors and Interventions in Patients with Heart Failure
Heart failure is a major public health challenge facing the world. The various clinical manifestations of heart failure can be described in three broad dimensions: left ventricular function, duration of heart failure symptoms, and functional limitations associated with heart failure. The 2022 EAPC document provides expert advice on mental health risk factors and interventions in patients with heart failure.
Link: guide.medlive.cn/guideline/25206
2022 AHA Scientific Statement: Strategies to Reduce Low-Value Cardiovascular Care
Low-value healthcare services have limited benefits for patients, and the 2022 AHA Scientific Statement describes the current scope and impact of low-value cardiovascular care and proposes solutions accordingly.
Link: guide.medlive.cn/guideline/25191
Famous teacher class, scan the code to enter
Public account entrance: The menu bar "Academic Dynamics" > a selection of "Boutique Courses" >"